Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

MLA

Mariana Brandão, et al. “Neoadjuvant Treatment for Intermediate/High-Risk HER2-Positive and Triple-Negative Breast Cancers: No Longer an ‘Option’ but an Ethical Obligation.” ESMO Open, vol. 4, no. 3, May 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....59581c60cc3ae12b123e75f2a2e6d73d&authtype=sso&custid=ns315887.

APA

Mariana Brandão, Martine Piccart-Gebhart, Fabien Reyal, & Anne-Sophie Hamy. (2019). Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation. ESMO Open, 4(3).

Chicago

Mariana Brandão, Martine Piccart-Gebhart, Fabien Reyal, and Anne-Sophie Hamy. 2019. “Neoadjuvant Treatment for Intermediate/High-Risk HER2-Positive and Triple-Negative Breast Cancers: No Longer an ‘Option’ but an Ethical Obligation.” ESMO Open 4 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....59581c60cc3ae12b123e75f2a2e6d73d&authtype=sso&custid=ns315887.